Android app on Google Play

BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform

January 14, 2013 7:43 AM EST Send to a Friend
Get Alerts HALO Hot Sheet
Price: $8.99 --0%

Rating Summary:
    8 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 9 | New: 58
Trade HALO Now!
Join SI Premium – FREE
BMO Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $12.00 (from $4.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $7.21 yesterday.




You May Also Be Interested In


Related Categories

Hot Upgrades, Upgrades

Related Entities

BMO Capital

Add Your Comment